KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Financing Activities (2016 - 2023)

TherapeuticsMD (TXMD) has disclosed Cash from Financing Activities for 13 consecutive years, with $2.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cash from Financing Activities rose 101.79% year-over-year to $2.0 million, compared with a TTM value of -$108.2 million through Dec 2023, up 54.0%, and an annual FY2023 reading of $3.2 million, up 101.34% over the prior year.
  • Cash from Financing Activities was $2.0 million for Q4 2023 at TherapeuticsMD, up from -$1000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $111.7 million in Q2 2019 and bottomed at -$120.0 million in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $9.2 million, with a median of $890500.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities surged 48669.82% in 2020, then crashed 28137.38% in 2022.
  • Year by year, Cash from Financing Activities stood at $77.0 million in 2019, then tumbled by 58.84% to $31.7 million in 2020, then plummeted by 95.73% to $1.4 million in 2021, then crashed by 8373.84% to -$111.9 million in 2022, then surged by 101.79% to $2.0 million in 2023.
  • Business Quant data shows Cash from Financing Activities for TXMD at $2.0 million in Q4 2023, -$1000.0 in Q3 2023, and -$111.9 million in Q4 2022.